Geneva Capital Management LLC Reduces Holdings in Mesa Laboratories, Inc. $MLAB

Geneva Capital Management LLC lowered its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 3.9% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 191,386 shares of the medical instruments supplier’s stock after selling 7,706 shares during the quarter. Geneva Capital Management LLC owned approximately 3.48% of Mesa Laboratories worth $12,825,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of MLAB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Mesa Laboratories by 4.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock valued at $364,000 after acquiring an additional 143 shares in the last quarter. Franklin Resources Inc. increased its position in Mesa Laboratories by 5.5% during the 2nd quarter. Franklin Resources Inc. now owns 3,476 shares of the medical instruments supplier’s stock worth $328,000 after purchasing an additional 182 shares in the last quarter. American Century Companies Inc. raised its stake in Mesa Laboratories by 1.5% in the 2nd quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock valued at $1,265,000 after purchasing an additional 194 shares during the last quarter. CWM LLC raised its stake in Mesa Laboratories by 48.9% in the 3rd quarter. CWM LLC now owns 597 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 196 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Mesa Laboratories by 30.9% during the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock worth $69,000 after buying an additional 243 shares in the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

Mesa Laboratories Stock Performance

Shares of NASDAQ MLAB opened at $80.60 on Thursday. Mesa Laboratories, Inc. has a 12-month low of $55.45 and a 12-month high of $131.20. The company has a market cap of $444.91 million, a PE ratio of 125.94 and a beta of 0.85. The stock has a 50 day simple moving average of $87.40 and a 200-day simple moving average of $78.22. The company has a current ratio of 1.94, a quick ratio of 1.45 and a debt-to-equity ratio of 0.86.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings results on Tuesday, February 3rd. The medical instruments supplier reported $3.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.41 by $0.66. The company had revenue of $65.13 million during the quarter, compared to analyst estimates of $63.23 million. Mesa Laboratories had a net margin of 1.51% and a return on equity of 22.02%. On average, equities research analysts forecast that Mesa Laboratories, Inc. will post 8 EPS for the current year.

Mesa Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 16th. Shareholders of record on Saturday, February 28th will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.8%. The ex-dividend date is Friday, February 27th. Mesa Laboratories’s dividend payout ratio is currently 100.00%.

Insider Transactions at Mesa Laboratories

In other news, Director Shiraz Shabanali Ladiwala bought 3,500 shares of the stock in a transaction on Tuesday, March 10th. The shares were purchased at an average price of $72.23 per share, for a total transaction of $252,805.00. Following the completion of the purchase, the director directly owned 8,523 shares of the company’s stock, valued at $615,616.29. This trade represents a 69.68% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director R Tony Tripeny acquired 1,315 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was purchased at an average price of $76.00 per share, for a total transaction of $99,940.00. Following the acquisition, the director directly owned 5,398 shares of the company’s stock, valued at $410,248. The trade was a 32.21% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have purchased 6,116 shares of company stock valued at $452,076. 4.90% of the stock is owned by insiders.

Key Headlines Impacting Mesa Laboratories

Here are the key news stories impacting Mesa Laboratories this week:

• Positive Sentiment: Several directors bought meaningful stakes this week (Shiraz S. Ladiwala 3,500 shares ~ $72.23, R. Tony Tripeny 1,315 shares ~ $76.00, Mark C. Capone 1,301 shares ~ $76.35). Multiple insider buys at these levels signal management confidence and can be interpreted as a bullish catalyst. Read More.
• Neutral Sentiment: Mesa announced a CEO transition naming Siddhartha Kadia as President & CEO. Leadership change is material — it can drive strategic refocus but may also introduce short‑term volatility until Kadia outlines priorities and execution plans. Read More.
• Negative Sentiment: Analyst skepticism and bearish commentary raise selling pressure: a recent Seeking Alpha piece questions valuation, and summary data show a high P/E and a 100% payout ratio on dividends — factors that heighten concerns about earnings sustainability and upside at current prices. Read More.

Analysts Set New Price Targets

MLAB has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Mesa Laboratories in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 7th. Zacks Research upgraded shares of Mesa Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. Finally, Wells Fargo & Company boosted their price target on Mesa Laboratories from $83.00 to $94.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 4th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $94.00.

Mesa Laboratories Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.